about
The value of source data verification in a cancer clinical trial.Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model.The effect of toothpaste concentration on enamel and dentine wear in vitro.Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.Bayesian analysis unravels pancreas-cancer adjuvant therapy.Assessing the quality of care for dying patients from the bereaved relatives' perspective: further validation of "Evaluating care and health outcomes--for the dying".Testing the equivalence of survival distributions using PP- and PPP-plots.The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints.Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design.Evaluation of a new silica whitening toothpaste containing blue covarine on the colour of anterior restoration materials in vitro.A robust parameterisation for the analysis of survival data in the presence of covariates with extreme value observations.Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: a prospective study.Application of methods for central statistical monitoring in clinical trials.Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.Time-series analysis of urethral electrical conductance measurements in the assessment of unstable urethral pressure: results in normal patients and in those with genuine stress incontinence.CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.Caring for those who die at home: the use and validation of ‘Care Of the Dying Evaluation’ (CODE) with bereaved relativesThe protective nature of pellicle towards toothpaste abrasion on enamel and dentineThe measurement of enamel wear by four toothpastesEvaluation of a 6% hydrogen peroxide tooth-whitening gel on enamel microhardness after extended useA quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systemsNatural history of alkaptonuria revisited: analyses based on scoring systemsAdjuvant therapy for pancreatic cancerManagement of large bowel obstruction with self-expanding metal stents. A multicentre retrospective study of factors determining outcome
P50
Q30582280-E0C96B7F-9BCD-4267-83CE-BDBCE88B52C6Q33655712-392A07DB-FA82-40F4-B297-24A3635D80BAQ34332808-0C06B2BB-66BD-4AAF-8D9F-120BCE60F8E3Q35085084-22317DF8-21F3-42B5-8FF5-2622E789C44FQ37711650-DABE8A50-9ACE-48F6-82CB-2A0548E8EA12Q42927225-0E1B3548-9AC3-450A-BD5F-3C70F80EF79FQ44299542-591EC5CB-A6D8-4C4E-A041-FFC92D6D5713Q44562975-BC1F1D2E-9EBA-4853-B87B-8B98EE477D5DQ45107556-B3ED7CBF-7EC6-4EAC-B1C8-71E4F247D4DCQ45940750-D2211830-85CE-497A-B705-32AE823DEB5AQ46011641-86EDEBB3-0548-432A-ACEB-0C45410B9325Q46408930-91DECC75-9604-4395-9207-FF64FF8DD0DFQ46417953-37F4E8D5-B798-4CDB-BB4A-824D1778D4F0Q46469721-07FE8525-3592-4282-8932-D7A6509164B9Q46743101-687A201A-1F90-4FD7-9AFE-A3B56D535C43Q48273508-4779DC65-BB7A-4030-95DC-86F3DE0F933EQ51150988-E214757A-5B67-4729-A1DD-6B9FC6E55A12Q51821033-717AE83F-C2DD-4177-9B47-840FA7E8A1EEQ52403791-F5D2FC8C-195E-4B1E-9F6C-3B178FC35622Q53101538-A73DD78C-7E31-4F47-AD60-F047034920BAQ60317221-1EC702E9-E53F-4629-917E-0B0B8C6128DCQ80793253-CF91298C-21F7-4605-BEE1-A617974427D1Q80898447-46077113-A0A3-4153-9019-54DBDA062F4AQ83017645-295E6F53-31E1-4C2B-9B78-52A81569B47FQ84534796-493A5DF8-0143-4DB0-BF53-8FDC2DD2E646Q84543165-06E46E00-D398-4BAF-85F5-ECA0EC5290A1Q85368927-DBECE3DF-DFF2-4709-AA6C-D02213DF5029Q87250992-481A1500-0499-4C4A-9C4A-E742E7B00CE4
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-3045-5594
@en
name
Trevor F Cox
@ast
Trevor F Cox
@en
Trevor F Cox
@es
Trevor F Cox
@nl
type
label
Trevor F Cox
@ast
Trevor F Cox
@en
Trevor F Cox
@es
Trevor F Cox
@nl
prefLabel
Trevor F Cox
@ast
Trevor F Cox
@en
Trevor F Cox
@es
Trevor F Cox
@nl
P106
P1153
7203000324
P31
P496
0000-0003-3045-5594